在研机构- |
权益机构- |
最高研发阶段无进展临床1期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
分子式C23H28F4N3O8PS |
InChIKeyDPIBBVZDLOOJRM-FTBISJDPSA-N |
CAS号1198784-97-2 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
胎儿炎症反应综合征 | 临床1期 | - | 2010-03-01 | |
关节炎 | 临床前 | 美国 | 2017-11-01 | |
关节炎 | 临床前 | 奥地利 | 2017-11-01 | |
内毒素血症 | 临床前 | 美国 | 2017-11-01 | |
内毒素血症 | 临床前 | 奥地利 | 2017-11-01 |
临床1期 | - | BI 653048 200 mg | 遞淵醖鬱簾廠壓積築積(壓淵築鏇網築製選廠廠) = Treatment with 200 mg BI 653048 was associated with a reduced expression of IL1R2, ITGB3, and SDPR versus 20 mg prednisolone; comparable levels of FKBP5, ZBTB16, and DDIT4 expression were observed. Changes in C-peptide, glucose, insulin, and cortisol were moderate compared with prednisolone. A greater reduction of osteocalcin was observed with 200 mg BI 653048 versus 20 mg prednisolone.Comparable anti-inflammatory efficacy was demonstrated for 200 mg BI 653048 and 20 mg prednisolone. 築積觸繭簾膚廠鹽餘觸 (鏇齋獵遞積鬱顧積襯構 ) 更多 | 积极 | 2019-05-04 | ||
prednisolone 20 mg |